FLT3 internal tandem duplications (FLT3‐ITD), detected in 20–30% of AML patients, have repeatedly been shown to correlate with prediction of disease relapse as well as with inferior overall survival [9, 10, 11]. This evidence concerns the gene FLT3 and acute myeloid leukemia.